Institute of Biomedical Materials and Engineering, College of Materials Sciences and Engineering, College of Chemistry and Chemical Engineering, Qingdao University, Qingdao, 266071, China.
Institute of Biomedical Materials and Engineering, College of Materials Sciences and Engineering, College of Chemistry and Chemical Engineering, Qingdao University, Qingdao, 266071, China; State Key Laboratory of Bio-Fibers and Eco-Textiles, Qingdao University, Qingdao, 266071, China.
Colloids Surf B Biointerfaces. 2019 Oct 1;182:110373. doi: 10.1016/j.colsurfb.2019.110373. Epub 2019 Jul 26.
Since the discovery of cisplatin for antitumor activity, the platinum (Pt) based antitumor drugs have received significant attention and launched a new era to explore the transition metal complexes for therapy. However, these small Pt-based antitumor drugs have some limitations for their clinic application, such as short blood circulation time and limited accumulation at tumor site, which was mainly due to their poor water solubility and small molecule size. To overcome these obstacles, developing new generation of transition-metal based complexes as anticancer agents is urgently needed. For the unique properties, the ruthenium (Ru) based complexes have attractive significant attention and be expected to be a substitute for Pt-based anticancer agents. Due to the nanometer size, unique geometry, relatively high surface charge and unique photophysical properties, the transition-metal based supramolecular coordination complexes (SCCs) which exhibited excellent antitumor efficiency and possessed desirable bioapplications such as drug loading, bioimaging and biosensing have attracted great attention as anticancer agents. In this minireview, we will highlight the recent development of ruthenium (Ru) and Platinum (Pt) based SCCs as potential anticancer agents.
自从顺铂被发现具有抗肿瘤活性以来，基于铂的抗肿瘤药物受到了极大的关注，并开创了一个探索过渡金属配合物用于治疗的新时代。然而，这些基于铂的小分子抗肿瘤药物在临床应用中存在一些局限性，例如血液循环时间短和在肿瘤部位的积累有限，这主要是由于它们的水溶性差和分子量小。为了克服这些障碍，迫切需要开发新一代基于过渡金属的配合物作为抗癌药物。由于独特的性质，基于钌（Ru）的配合物引起了人们的极大关注，并有望替代基于铂的抗癌药物。由于纳米尺寸、独特的几何形状、相对较高的表面电荷和独特的光物理性质，表现出优异的抗肿瘤效率并具有药物负载、生物成像和生物传感等理想生物应用的基于过渡金属的超分子配位配合物（SCCs）作为抗癌药物引起了极大的关注。在这篇综述中，我们将重点介绍基于钌（Ru）和铂（Pt）的 SCCs 作为潜在抗癌药物的最新进展。
